A study of the effect of long-term anticholinergic administration -solifenacin succinate-

A study of the effect of long-term anticholinergic administration -solifenacin succinate- - A study of the effect of long-term anticholinergic administration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017260

Enrollment

100

Registered

2015-04-24

Start date

2008-12-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

Solifenacin succinate 5 mg will be orally administered once a day after breakfast for 52 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)OAB patients (urgency score (OABSS) >= 2 and OABSS total score >= 3) 2)Residual urine volume <100ml 3)Patients from whom we have received written consent.

Exclusion criteria

Exclusion criteria: 1)Patients who has contraindication of solifenacin succinate 2)Patients with prostate cancer 3)Patients with dutrusor underactivity 4)Patients with history of urethral stricture 5)Patients with history of radiation therapy 6,7)Patients with bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis. 8)Patients with using self catheterization 9)Patients with history of resistance to anti-holinergic agents 10)Any other patients who are regarded as unsuitable for this study by the investigator

Design outcomes

Primary

Measure	Time frame
We explore the factors that affect their usefulness in agent.	—

Countries

Japan

Contacts

Public ContactHiroshi Tanaka

Hokkaido University Graduate School of Medicine Department of Renal and Genitourinary surgery

h-tanaka@med.hokudai.ac.jp011-706-5966

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026